Background: It is well known that selective serotonin reuptake inhibitors (SSRIs) can cause sexual dysfunction, so it is possible that sibutramine, a serotonin and norepinephrine reuptake inhibitor, could induce sexual dysfunction. Design and subjects: The effect of sibutramine on sexual function was evaluated in 46 overweight and obese (body mass index (BMI) X23 kg/m 2 ) but otherwise healthy married women (28-44 years). Participants were randomly assigned at baseline to either the sibutramine or control group. The Female Sexual Function Index (FSFI) questionnaire was used to assess sexual function at baseline and after treatment with behavioral therapy plus sibutramine 10 mg once daily or behavioral therapy alone (control) for 8 weeks.
Introduction
Female sexual dysfunction is identified by DSM-IV based on the phases of human sexual response, namely, desire, excitement, orgasm, resolution. 1 These phases have been used widely in studies investigating female sexual response. The desire phase of sexual response is closely associated with the balance between the dopamine-sensitive excitatory center and the serotonin-sensitive inhibitory center. 2 It is thought that a drug that increases serotonin activity in the brain may affect the patient's sexual desire and change their sexual function. Indeed, those who take selective serotonin reuptake inhibitors (SSRIs), the drugs of which are most commonly prescribed for depression, reported diminished sexual desire, arousal, sensitivity and orgasm. 3 Dose-dependent sexual dysfunction is one of the most commonly reported side effects of treatment with SSRI antidepressants 4, 5 and has been reported with the use of SSRI,
fluoxetine (Prozac s
. Although not approved for use as a weight-loss agent, treatment with fluoxetine has also been shown to result in weight loss over the short term. 6 Sibutramine (Reductil s ) and orlistat (Xenical s ) approved in 1997 and 1999, respectively, by the FDA in the US for the treatment of obesity are the only weight loss medications approved for use beyond 3 months. 7 Sibutramine is thought to work by inhibiting the reuptake of both serotonin and norepinephrine in the hypothalamus 8 and it was originally developed as an antidepressant 9 rather than as a drug designed to affect weight loss. Because of this mode of action, hypothetically, the use of sibutramine might increase the likelihood of eliciting sexual dysfunction similar to that demonstrated by the use of fluoxetine. To date, we have found no evidence of any study conducted with sibutramine on sexual function. Therefore, authors decided to assess the effects of sibutramine-induced weight loss on sexual function in a group of overweight and obese women in Korea.
Materials and methods
The study was conducted in married women who were obese and still menstruating regularly but without any other documented health problems. As it was important that the subjects be comfortable talking about their personal sexual habits, the study recruited married women. All subjects were premenopausal. The body mass index (BMI) of individual subjects was 23 kg/m 2 or higher, which is used as a cutoff point for overweight in the Asia-Pacific region. 10, 11 All subjects met the requirement that they were having sexual intercourse at least once a month. Subjects were excluded who had a diagnosis of hypertension or were taking antihypertensive medicine or had known cardiovascular disease. Also excluded were subjects who had other chronic illness such as diabetes or neurological disease, subjects with an abnormal hematological profile, abnormal creatinine levels and/or thyroid function test, subjects taking any type of medication or receiving any kind of medical treatment during the previous 1 month prior to enrolment into the study. Also contraindicated were subjects with a history of psychiatric conditions, hysterectomy or other procedures that might impact sexual function. As the use of sibutramine in pregnant and breast-feeding mothers is contraindicated and weight loss per se is not recommended during pregnancy, pregnant women and breast-feeding mothers were also excluded. It is also known that both pregnancy and breast-feeding can impact sexual function; therefore, subjects were encouraged not to become pregnant during the study period and any subject who became pregnant was withdrawn from study medication.
All subjects were briefed on the research procedures, and a written consent for participation was obtained from each subject. The Severance Hospital Institutional Review Board approved this study.
The treatment period was 8 weeks. Subjects were randomized to treatment with behavioral therapy plus sibutramine 10 mg once daily or behavioral therapy only (control group) at baseline. All subjects were required to visit the hospital every 2 weeks (five visits in total) to receive behavioral therapy for obesity based on the LEARN program developed by Brownell. 12 Under the program, subjects were counseled on how to modify their behavior and diet (based on a 1500 kcal/day allowance) and how to increase their overall exercise. Compliance with the guidelines was assessed at each of these bi-weekly visits. Body weight, height and waist circumference were determined before commencing study medication and at end point. Height was measured to the nearest to 0.1 cm, and weight to the nearest to 0.1 kg with the subjects wearing light clothing and with an empty stomach. BMI was calculated as weight in kilograms divided by the square of the height in meters. Waist size was measured to the nearest to 0.5 cm by the same person following the instructions suggested by NIH. 7 Bioelectrical impedance analysis was used to measure body composition using an InBody 2.0 analyzer, manufactured by Biospace Co. Subjects were to have an empty stomach and stand relaxed for 5 min before measurement took place.
The subjects completed the self-report Female Sexual Function Index (FSFI) questionnaire, published by Rosen et al., 13 to rate their level of sexual function before starting the study and after the 8-week treatment period. As the FSFI questionnaire was designed to collect data over 1-month periods, baseline FSFI was completed by the subjects prior to starting study medication and the subsequent questionnaire collected data on sexual function between weeks 5 and 8. The author and an English language expert translated the FSFI questionnaire into the Korean language. This version was back-translated into English by a second English language expert who was not aware of the content of the original questionnaire. The back-translated questionnaire was verified and approved for use by Leiblum who developed the original FSFI questionnaire. The primary efficacy variable was the change in FSFI before and after treatment; changes in weight, BMI, waist circumference, fat body mass, fat-free mass, cholesterol, triglycerides, HDL and LDL were assessed as secondary variables.
All statistical analyses used statistical analysis system (SAS) for Window (version 8.01). t-Test was performed to test a statistical significance of mean differences in the overall group of subjects or those who completed the study. Where the sample size was too small for normal distribution, nonparametric methods were used. Wilcoxon's rank sum test was used to compare characteristics between subjects who completed the study and those who did not. Wilcoxon's signed rank test was used to assess changes in variables in subjects after treatment. A correlation analysis was performed to identify health parameters related to changes in FSFI total score and individual domain scores (D1, desire; D2, arousal; D3, lubrication; D4, orgasm; D5, satisfaction; D6, pain).
Results
A total of 46 subjects (age range 28-44 years) met the inclusion criteria and were enrolled into the study; 24 were randomized to the sibutramine 10 mg treatment group and 22 to the control group. At baseline, there was no significant difference between the groups in terms of age, height, body weight, BMI and FSFI; however, mean waist circumference in the sibutramine group was smaller than that of the control group (Table 1) .
A total of 10 subjects prematurely withdrew from the study: four in the sibutramine treatment group and six in the control group. There was no statistically significant difference in terms of baseline characteristics between subjects who withdrew prematurely and those who completed the study. Data from two subjects in the control group relating to the FSFI questionnaire were excluded from the analysis of Effect of sibutramine on female sexual function KK Kim et al change in sexual function, as the subjects did not have sexual intercourse during the final month of the study before completing the questionnaire.
At week 8, there was a statistically significantly greater mean reduction in both body weight and BMI in sibutramine-treated subjects who completed the study compared to subjects in the control group (Po0.0001). Waist circumference was reduced in both treatment groups but the fact that no statistically significant difference based on a two-tailed test (P ¼ 0.097) was found between the groups is probably related to the smaller mean waist circumference of the sibutramine treatment group at baseline. Significance in favor of sibutramine was seen based on a one-tailed test (Po0.05) ( Table 2) .
There was no statistically significant difference between groups in triglycerides, total cholesterol, LDL cholesterol or HDL cholesterol. The mean absolute changes in LDL and total cholesterol from baseline to end point in the sibutramine treatment group were, however, significantly different from zero (Po0.05) ( Table 2 ). Bioimpedance analysis revealed a statistically significant reduction of fat body mass in the sibutramine treatment group compared to the control group (P ¼ 0.001) ( Table 2) .
Changes in FSFI are presented in Table 3 . There was no significant change from baseline to week 8 in the control group in FSFI total score and individual domain scores except for orgasm domain score (D4), which fell after treatment (P ¼ 0.011). Subjects in the sibutramine group exhibited significant improvement from baseline in FSFI total score (P ¼ 0.0132) and the domain scores relating to arousal (D2) (P ¼ 0.0179) and lubrication (D3) (P ¼ 0.0313). There was a statistically significant difference (Po0.05) between the groups in favor of sibutramine for FSFI total score and in the domain scores relating to arousal (D2), orgasm (D4) and satisfaction (D5).
To determine which variables may have had a positive impact on FSFI, a correlation analysis was performed based on the data from both treatment groups combined to determine the relationship between changes in FSFI total, and individual domain scores and health parameters, including body weight, BMI, waist circumference, fat body mass and fat-free mass (Table 4) .
No correlation was seen between any variable and improvement in desire, lubrication, satisfaction domains and FSFI total score. Decrease in body weight and BMI had a positive impact on arousal (r ¼ À0.44 and r ¼ À0.48, respectively) and orgasm (r ¼ À0.45 and r ¼ À0.46, respectively). The results also revealed a tendency for lower pain domain scores to be positively correlated with decrease in body weight, BMI and body fat mass; body fat mass and changes in the pain domain score showed a particularly significant correlation (r ¼ 0.48). Two of 16 control group completion participants answered that they had had no sexual activity during the past 1 month at the end of the study. Their FSFI scores were considered outliers, so they were removed from FSFI analysis. Effect of sibutramine on female sexual function KK Kim et al
Discussion
The purpose of this study was to assess the impact of the weight-loss drug, sibutramine, on sexual function. Given differences in physiology of sexual response and assessment criteria for sexual performance between men and women, the study focused on female sexual function only. Female sexual function can be evaluated from physiological measurements, such as the amount of blood flow in the vagina, but a self-reporting questionnaire, such as the FSFI used in this study, is considered the most appropriate measurement method. The FSFI questionnaire is simple, economical and effective, reflecting actual sexual function in the normal environment. This questionnaire requires less explicit sexual descriptions than other questionnaires and helps subjects reveal their sex life without being provoked. 14, 15 In addition, the FSFI has a verified numeric rating scale system, enabling investigators to easily determine any improvement in sexual function.
With the exception of polycystic ovary syndrome (PCOS), there is limited information available on the relationship between obesity, weight reduction and female sexual function. The conclusions from studies in subjects with PCOS cannot be applied to the overall obese female population, as PCOS exhibits several specific endocrine features. 16 It is also important to recognize that the majority of studies that have examined the effects of weight reduction on female sexual function have used unvalidated tools to measure sexual function. It is unclear whether obese women have sexual dysfunction more often than non-obese women. In young women, clinical trial data suggest an ambiguous association between obesity and sexual satisfaction. [17] [18] [19] However, weight reduction seems to improve sexual function in obese women. 20, 21 Of several mechanisms that could contribute to an overall change in sexual function after weight reduction in obese young women, alteration of the sex hormones estrogen and androgen and improvement in body image are the most important. Whether a change in sex hormone status is an appropriate explanation for an improvement in sexual function is difficult to determine because estrogen and androgen levels either do not change significantly or, in fact, are reduced after weight loss.
Estrogen is produced from cholesterol in the ovaries or by aromatization of steroids in the adipose tissue. A reduction in fatty tissue, therefore, can result in decreased levels of blood cholesterol, aromatization and estrogen. However, among premenopausal women, the far greater effect of ovarian estrogen secretion would exceed any decreased estrogen levels that occur through weight reduction. 22 Estrogen levels tend to decrease after weight loss, which could directly influence the FSFI questionnaire domains of both lubrication and pain resulting in an increase in sexual pain. In this study, however, the results for the sexual pain domain showed no treatment change and no between-group difference. The lubrication domain showed no correlation to changes in fat body mass but did show an increase for sibutramine-treated subjects who lost the most weight (especially in terms of body fat). The small sample size may have affected the sensitivity of the instruments to detect treatment differences.
Several studies have reported that in regularly menstruating obese women, changes in androgen levels after weight reduction indicate that sex hormone-binding globulin consistently increases after weight loss and, in turn, free testosterone seems to decrease. [23] [24] [25] Androgen insufficiency is related to hypoactive sexual desire disorder 14, 26 and androgen, in contrast, can increase sexual desire, arousal, orgasm and satisfaction. 27, 28 Weight reduction, therefore, can reduce the score in each of these domains. The sibutramine group in this study exhibited improvement in not only FSFI total score, but also in a number of individual domain scores, displaying statistically meaningful results in arousal and lubrication domains and FSFI total score. However, the control group, which showed no significant weight change, also showed no significant change in FSFI total score or other individual domain scores, except the orgasm domain. When comparing the two groups, the sibutramine group had greater improvement than the control group in the domains of arousal, orgasm Effect of sibutramine on female sexual function KK Kim et al and satisfaction and FSFI total score. Data from two control subjects were excluded from this analysis, as the subjects had no sexual activity during the assessment period; if, however, these data had been included in the analysis, the improvement in sexual function achieved by the sibutramine group would be more favorable.
Some weight-loss trials report simultaneous improvement in both body image and sexual function in women. 20, 29 To test whether the positive impact of sibutramine-induced weight loss on sexual function is likely to be associated with the amount of weight loss and improved body shape, a correlation analysis was performed to estimate this relationship. As presented in Table 4 , a decrease in weight and BMI had a positive impact on sexual function, especially in arousal and orgasm domains, but there was no correlation between loss in body fat and improvement of sexual function. Therefore, it is weight loss itself rather than improvement of body shape that is considered to play a greater role in improving sexual function. Arousal disorder (the female equivalent of impotence) can be measured by the FSFI questionnaire's arousal and lubrication domains. This study revealed that following treatment with sibutramine plus behavioral therapy, the arousal domain score increased, exceeding that of the control group, and that the lubrication domain score also rose but without a significant difference from the control group. The satisfaction domain score, although only slightly improved in the sibutramine group, showed a meaningful difference between the two treatment groups, indicating that neither sibutramine nor weight loss is likely to decrease blood flow to the vagina or to decrease lubrication, but appears to improve arousal and satisfaction in combination with other factors, among which is the degree of weight loss. Unlike other SSRIs, treatment with sibutramine plus behavioral therapy did not cause arousal disorders in this study.
The FSFI orgasm domain score decreased in the control group after treatment, whereas almost no change was observed in the sibutramine group. The correlation analysis showed a tendency of higher orgasm domain scores in participants whose weight decreased.
Mean weight reduction in the sibutramine treatment group in this study was almost 4 kg, equivalent to an approximate fall of 6% from baseline. This is in contrast to other published data with sibutramine where a weight reduction of approximately 4% was achieved during the first 8 weeks of administration. 30, 31 The minimal weight loss (o0.5 kg) achieved by the control group, which was less than that reported previously using a similar behavioral modification program (3.8-4.2 kg), 32 could be related to the slightly longer time interval (2 weeks) between clinic visits and to the lower BMI inclusion criteria (X23 kg/m 2 ). Treatment with sibutramine plus behavioral therapy improved body composition by decreasing body fat and increasing fat-free mass. At the same time, changes in lipid profile were characterized by a clinically relevant decrease in total cholesterol and LDL cholesterol. A number of studies state that sibutramine treatment decreased triglyceride and increased HDL but did not show clinically relevant changes in LDL cholesterol level. [33] [34] [35] The decrease in LDL cholesterol level achieved in this study may be attributable to the combined behavioral therapy, which includes increased exercise. According to the data from a study of female sexual function treatment, we cannot neglect the placebo effect on sexual function. 36 The fact that this was not a placebocontrolled study is a limitation. However, this study tried to avoid any possibility of affecting how participants answered the questionnaire by not discussing sexual issues throughout the treatment period, and by emphasizing weight reduction. Depression has been related to the alteration of sexual function, 37 and can be related to female sexual dysfunction. 38 Therefore, we tried to exclude from the study all persons who had any medical history of psychiatric treatment and asked participants whether they had symptoms of a major depressive episode at screening. However, we did not use a validated method to detect the presence or change of mood in this study, which may constitute a bias.
In conclusion, weight reduction induced by sibutramine plus behavioral therapy enhanced overall sexual function in overweight and moderately obese women, and showed statistically significant results in arousal, orgasm and satisfaction domains. This result is more likely related to the degree of weight loss, regardless of the use of sibutramine. It is possible that the strong effect of 'self body image after weight reduction' on sexual pleasure obscured a smaller effect of sexual function impairment by sibutramine. But sexual arousal and satisfaction, which have been thought to be unfavorably influenced by sibutramine, showed improvement after treatment with sibutramine plus behavioral therapy, and the orgasm domain showed no change after treatment with sibutramine plus behavioral therapy. These results suggest that the beneficial effects resulting from weight loss far exceed any deterioration of sexual function that might be caused by sibutramine.
In this study, we concluded that treatment with sibutramine plus behavior therapy for women who are overweight or moderately obese was not associated with deterioration in sexual function. Instead, weight loss induced by sibutramine plus behavioral therapy enhanced sexual function, indicating that improvement in sexual function was closely linked to the degree of weight loss.
